Ginkgo Bioworks Holdings EBITDA 2020-2023 | DNA
Ginkgo Bioworks Holdings ebitda from 2020 to 2023. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Ginkgo Bioworks Holdings Annual EBITDA
(Millions of US $) |
| 2022 |
$-2,165 |
| 2021 |
$-1,799 |
| 2020 |
$-123 |
| 2019 |
$-61 |
Ginkgo Bioworks Holdings Quarterly EBITDA
(Millions of US $) |
| 2023-03-31 |
$-197 |
| 2022-12-31 |
$-218 |
| 2022-09-30 |
$-644 |
| 2022-06-30 |
$-637 |
| 2022-03-31 |
$-666 |
| 2021-12-31 |
$-1,677 |
| 2021-09-30 |
$-18 |
| 2021-06-30 |
$-53 |
| 2021-03-31 |
$-51 |
| 2020-12-31 |
|
| 2020-09-30 |
$-34 |
| 2019-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$3.379B |
$0.478B |
|
Ginkgo Bioworks platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo Bioworks, formerly known as Soaring Eagle Acquisition Corp., is based in NEW YORK.
|
